Vermillion Sets Fourth Quarter and Full Year 2013 Conference Call for Thursday, March 6, 2014

    Vermillion Sets Fourth Quarter and Full Year 2013 Conference Call for                            Thursday, March 6, 2014  PR Newswire  AUSTIN, Texas, Feb. 26, 2014  AUSTIN, Texas, Feb. 26, 2014 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, will hold a conference call on Thursday, March 6, 2014, at 4:30 p.m. Eastern time to discuss results for the fourth quarter and year ended December 31, 2013. Financial results will be issued in a press release prior to the call.  Vermillion's President and CEO Thomas McLain will host the call, followed by a question and answer period.  Date: Thursday, March 6, 2014 Time: 4:30 p.m. Eastern time (3:30 p.m. Central time) Dial-in number: 1-800-763-6049 International dial-in number: 1-212-231-2932 Conference ID: 21709303 Webcast: http://edge.media-server.com/m/p/ee5rni5o/lan/en  The conference call will be webcast live and available for replay via the investor section of the company's website at www.vermillion.com.  Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.  A replay of the call will be available approximately two hours after the call until March 20, 2014.  Toll-free replay number: 1-800-633-8284 International replay number: 1-402-977-9140 Replay ID: 21709303  About Vermillion Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.  The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.  Investor Relations Contact: Liolios Group, Inc. Ron Both Tel 1-949-574-3860 vrml@liolios.com  SOURCE Vermillion, Inc.  Website: http://www.vermillion.com